This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Jan 2011

FDA Grants Supplemental Approval for Actemra (tocilizumab)

ACTEMRA now includes labeling for the inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in rheumatoid arthritis.

Related News